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Oral Presentations 29hematopoiesis are critical for the development of a more comprehen-
siveknowledgeofnormalhematopoiesis, stemcell homing, trafficking,
differentiation and hematopoietic pathology. Growth and renewal in
many tissues are initiated by stem cells, supported by the microenvi-
ronment (niche) in which they reside. While recent work has begun
to describe functional interactions between stem cells and their niches,
little is known about the formation of stem cell niches.
Methods & Results: We established a functional, in vivo assay
(via implantation of cells under the renal capsule) to isolate
the determinants of hematopoietic stem cell (HSC) niche
formation and activity. Using this novel assay, we show that a pop-
ulation of progenitor cells (CD45-Tie2-aV1CD1051Thy1.1-;
CD1051Thy1-) sorted from 15.5 dpc fetal limbs and transplanted
under the adult mouse renal capsule recruit host-derived vascula-
tures in a VEGF dependent manner, produce donor-derived
ectopic bones through endochondral ossification, and generate
a marrow cavity populated by host-derived long term reconsti-
tuting HSC (LT-HSC). In contrast, CD45-Tie2-aV1
CD1051Thy1a1 (CD1051Thy11) progenitors form bone that
does not contain a marrow cavity. While analyzing these and other
sorted populations, we did not observe any instances where niche
was present without bone, suggesting that skeletal progenitors
are necessary for initiating an HSC niche but osteoblasts alone
cannot initiate and support niche activity. Suppression of factors
important for HSC maintenance, such as steel factor (SLF),
in progenitor populations prior to transplant did not alter their
ability to initiate and support an HSC niche. On the other hand,
suppression of factors involved in endochondral ossification, such
as osterix and VEGF, inhibited niche generation. Furthermore,
CD1051Thy1- progenitor populations derived from regions of
the fetal mandible or calvaria that do not undergo endochondral
ossification form only bone without marrow in our assay.
Conclusions: In addition to identifying the limb-derived skeletal
progenitor capable of endochondral ossification involved and the
basic mechanisms ofHSCniche initiation, our study provides a func-
tional framework by which future studies onHSC-niche interactions
at the cellular level can be carried out.70
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Cord blood (CB) is a viable alternative to bone marrow (BM) or
mobilized peripheral blood (mPB) for transplantation.While CB is
collected, typed, frozen and banked as a readily available source of
ethnically-diverse tissue for transplant, a major limitation of CB
transplantation is low cell dose leading to delayed engraftment
and increased risk of engraftment failure. Ex vivo expansion of
CB could improve transplant outcomes by increasing cell dose. Us-
ing a mesenchymal stem cell (MSC) co-culture system, significant
levels of CD341 cell expansion can be achieved. However, the pres-
ence of non-CD341 accessory cells may impact the efficiency of
expansion. Thawed CB units contain (mean 6 SEM, n 5 114)
1.4 6 0.6% CD341, 39.5 6 1.2% CD31, 17.1 6 0.7% CD191,
15.3 6 0.7% CD141 and 20.1 6 1.2% CD561 cells. Preliminary
experiments demonstrated that only CD31 and/or CD141 in-
hibited CD341 expansion. No positive or negative impact was ob-
served for any other cell population. These data suggested CD31
and CD141 cells as candidate populations for investigation. Our
hypothesis is that the depletion of CD31 and/or CD141 cells
from CB MNC will markedly improve CD341 expansion in the
MSC co-culture system.
Methods:CD31 and/or CD141 cells were removed from a single
CB unit by magnetic depletion (MACS, Miltenyi) and the products
cultured in theMSC co-culture system. Comparisons were made be-
tween the CD341 and total nucleated cell (TNC) expansion
achieved in the MSC co-culture system following the incubation of
MNC (nothing depleted), MNC depleted of CD31 cells (MNC-
CD31), CB MNC depleted of CD141 cells (MNC-CD141) and
CB MNC depleted of both CD31 and CD141 cells (MNC-
(CD31 1 CD141)). Incubations were performed in mediumcontaining Flt-3L, SCF, G-CSF and TPO for 7 days. On day 7,
non-adherent (n/a) cells were removed and cultured in liquid culture
conditions (no MSC) for a further 7 days. On Day 14, n/a cells from
the co-culture flask and liquid cultures were pooled and evaluated for
TNC and CD341 cell content.
Results:
Fold increase over input (range: min-max, n53)
TNC CD341MNC 3.5-19.8 11.3-12.4
MNC-CD31 21.2-47.4 19.2-51.3
MNC-CD141 8.3-27.0 23.6-32.4
MNC-(CD31 1 CD141) 27.8-41.0 23.9-55.1Conclusion: The depletion of CD31 and/or CD141 cells from
the CB MNC increased ex vivo expansion of TNC and CD341
when compared with original CBMNC expansion. GMP-compliant
antibodies that target CD3 and CD14 are available (Miltenyi) and
could be used for clinical evaluation of this strategy.SUPPORTIVE CARE
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NEW MOBILIZATION STRATEGIES FOR COLLECTION OF PERIPHERAL
BLOOD PROGENITOR CELLS FOR LYMPHOMA AND MYELOMA PATIENTS
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Autologus stem cell transplantation (SCT) is a common treat-
ment modality for lymphoma and myeloma patients. The success
of SCT depends on the collection of adequate number of CD34
positive cells. Standard mobilization therapy consits of granulo-
cyte-colony-stimulating factor G-CSF and Sargramostine (GM-
CSF). Some patients that are mobilized with G-CSF alone fail to
collect the target cell dose while others are able to collect target
dose after numerous apheresis procedures. In Autologus progenitor
cell moblizaton, the addition of chemotherapy in conjunction with
G-CSF/GM-CSF can substantially increase the yield of CD34
peripheral blood progenitor stem cells (PBSC), it is not without
significant toxicities, additional cost and quality of life issues.
Inadequate stem cell mobilization is seen in approximtely 25% of
patients undergoing autotransplantation for hematologic malig-
nancies. Experience has shown that patients who fail initial mobili-
zation are likely to fail remobilization. Alternative strategies are
needed for donors who fail to mobilize adequate number of stem
cells with standard therapy. Plerixafor (AMD 3100) is a new and
promising agent being studied for use in mobilization of preipheral
blood progenitor cells in patients with lymphoma and myeloma.
AMD 3100 is a bicyclam derivate that specifically and reversibly in-
hibits binding of SDF-1 to its receptor CXCR4 leading to stem cell
mobilization. Plerixafor can be used alone or in conjunction with
G-CSF for stem cell mobilization. Two phase III, multicenter, ran-
domized, double-blinded, placebo-controlled studies compared
AMD3100 plus G-CSF with G-CSF alone for mobilization of
stem cells in patients with myeloma and NHL. Patients recieved
G-CSF at 10ug/kg/day subcutaneoulsy for 4 days and on the even-
ing of the fourth day they recieved either AMD3100 at 240 ug/kg
subcutaneously or placebo. The aphereses started on day five, after
the morning dose of G-CSF, and continued until CD341was#5
106/kg (NHL) or #6  106/kg (MM) or total of four collections.
Patients continued recieving their morning doses of G-CSF and
evening dose of study drug until collection was complete. Patients
who falied to collect#2 106CD341 cells/kg were eligible for res-
cue with AMD3100 plus G-CSF. These studies confirmed that the
addition of AMD3100 to G-CSF is safe and well tolerated. Patients
mobilized with AMD3100 plus G-CSF were more likely to achieve
a target CD341 cell count with less apheresis and had successful
transplant.
